Autres langues Alligator Bioscience AB London S.E.

Actions

0RK9

SE0024173637

Recherche biotechnologique et médicale

Temps Différé London S.E. 12:55:48 18/12/2025			Varia. 5j.	Varia. 1 janv.
0,3209 ^SEK	-99,99%		+1 428,10%	-0,28%

10:26	20 actions ont atteint aujourd’hui un nouveau plus bas sur 52 semaines à la Bourse de Stockholm	FW
05/10	La Bourse de Stockholm en léger repli lundi, l’indice OMXS30 reculant de 0,1 %	FW

Autres langues

05/10	Alligator Bioscience: CFO Johan Giléus to Take Over as CEO
05/10	Alligator Bioscience Names Finance Chief as New CEO
04/10	Alligator Bioscience : appoints Johan Giléus as CEO - Søren Bregenholt to step down at year-end
04/10	Alligator Bioscience appoints Johan Giléus as CEO – Søren Bregenholt to step down at year-end
29/09	Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue
22/09	Alligator Bioscience announces final outcome in rights issue
21/09	Alligator Bioscience: 17% Preliminary Subscription Rate
21/09	Alligator Bioscience announces preliminary outcome in rights issue
07/09	Alerts on Alligator Bioscience conducting rights issue withdrawn
31/08	Alligator Bioscience publishes prospectus in connection with rights issue
28/08	Alligator Bioscience (Q2 2026 Review): The HLX22 waiting game
26/08	Bulletin from the extraordinary general meeting in Alligator Bioscience AB
26/08	Alligator Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
26/08	Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update
20/08	Alligator Bioscience : Invitation to Alligator Bioscience's earnings call on 26 August 2026
20/08	Invitation to Alligator Bioscience’s earnings call on 26 August 2026
23/07	Notice of extraordinary general meeting in Alligator Bioscience AB
23/07	Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans
02/07	Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer
02/07	Alligator Bioscience Doses First Patient In Investigator-Initiated Study Of Intratumoral Mitazalimab In Early-Stage Breast Cancer
08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22
08/06	Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with Hlx22
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22
08/05	Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III
06/05	Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026